美国IPO上周回顾：NIQ表现不佳，Accelerant在7家IPO公司中表现出色 上周有七家公司首次公开募股 (IPO)，一家小型IPO和五家SPAC提交了初始申请。 消费者情报提供商NIQ Global Intelligence ( NIQ ) 的IPO定价低于中间价，以62亿美元的市值筹集11亿美元。该公司是一家领先的全球 消费者情报公司，其业务遍及全球90多个国家，覆盖全球约85%的人口、超过全球GDP的一半，截至2024年12月31日，全球消费者支 出超过7.2万亿美元。近年来，在强劲的留存率的帮助下，该公司的收入有所增长，尽管它仍然处于亏损状态，自由现金流为负。NIQ Global Intelligence下跌了6%。 专业保险市场Accelerant ( ARX ) 将其扩大后的IPO定价高于区间，以47亿美元的市值筹集7.24亿美元在其风险交易所的"供应方"，该公 司为会员提供全方位服务；而在"需求方"，该公司为风险资本合作伙伴提供专业保险费组合，这些保险费在其他平台可能难以获得。 截至2025年3月31日，Accelerant平台拥有232名会员和96名风险资本合作伙伴。上周收盘上涨42%。 ...

Company Overview - Carlsmed, a medical technology company specializing in personalized spinal surgery using artificial intelligence, completed an IPO raising $100.5 million by issuing 6.7 million shares at $15 each [1] - The company is headquartered in Carlsbad, California, and has a market capitalization of approximately $397.7 million based on the disclosed number of shares [1] - Major institutional investors include B Capital Group and US Venture Partners, with their ownership diluted to 26.3% and 21.2% respectively post-IPO [1] Financial Performance - For the first three months of 2025, Carlsmed reported revenues of $10.2 million and a net loss of $5.7 million, compared to revenues of $5.1 million and a net loss of $5.4 million in the same period last year [2] - As of March 2025, approximately 177 surgeons have utilized Carlsmed's platform for surgeries, a significant increase from 103 users in the previous year [2] Market Context - The IPO occurs amid a downturn in the U.S. healthcare IPO market, with only $2.1 billion raised by new listings in 2025, nearly a 50% decrease compared to the same period in 2024 [2] - The IPO is underwritten by major financial institutions including Bank of America, Goldman Sachs, and Piper Sandler, with shares set to trade on the Nasdaq Global Select Market under the ticker symbol CARL [2] Technology and Future Plans - Carlsmed's aprevo technology platform is currently approved for lumbar fusion surgeries, with plans to develop solutions for cervical fusion surgeries expected to be commercialized by 2026 [1]

Company Overview - Carlsmed Inc. plans to raise up to $107.2 million through an IPO, with a proposed share price range of $14 to $16 for 6.7 million shares, potentially valuing the company at approximately $424.3 million [1][2] - The company specializes in personalized surgical solutions and custom spinal implants using its AI technology platform, aprevo, which is currently approved for lumbar fusion surgeries [2] Financial Performance - For the first three months of 2025, Carlsmed reported revenues of $10.2 million and a net loss of $5.7 million, compared to revenues of $5.1 million and a net loss of $5.4 million in the same period the previous year [1] Market Context - The healthcare sector's IPO financing has been sluggish, with only $2.1 billion raised by new companies in this sector in 2025, representing a decline of over 40% compared to the same period in 2024 [1] - Carlsmed's major investors include B Capital Group and US Venture Partners, holding 35.1% and 28.3% of shares respectively prior to the IPO [2] Technology Development - The company is developing a version of its aprevo platform for cervical fusion surgeries, expected to be commercially available by 2026 [2] - As of March 2025, approximately 177 surgeons have utilized the aprevo platform for surgeries, an increase from 103 surgeons in the previous year [2] IPO Details - The IPO is being led by Bank of America, Goldman Sachs, and Piper Sandler Cos., with the stock expected to trade under the ticker symbol CARL on the Nasdaq Global Select Market [2]